{"name":"Menarini Group","slug":"menarini-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxPYW9BLWZ4aUw4eHNFeXZ3cWhhMmp4SF9MVkhDcUdJZjdLWXhPczBMMXVaMnZNMm53MTI5bWxXWlpSVG1HRlVPN1dIWGdfaTJyNWNZcVRNOThJaFIwVVk4Tl9hTThCZWE5UFExUlJrbnd5R3NTUFBuSGdtdUJfTUV1XzMwN0hCSkx2Sk9ja2JwaXE1ek9DcDZ3ZDZiSG5LOXpUa19hWHpXYm9jajd0ZjdmZVJ5LVZCM3QtRldncXB1VlFQNk14MVdQLVpoelU0SGNqcGczdUV4QXJNNHVvTjlKaUNuT2JRM0NxU2hZMHFHaGRaWDBxa2YtUQ?oc=5","date":"2026-03-09","type":"pipeline","source":"GlobeNewswire","summary":"Menarini nears €4.9 billion in 2025 and focuses on talent and AI as ‘giant’ players enter pharma - GlobeNewswire","headline":"Menarini nears €4.9 billion in 2025 and focuses on talent and AI as ‘giant’ players enter pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOX3BQTUZHZW5PVmFSa1BsQWhoZkI3Mkx2MjhTX3lBRl9rcnF6d21wNG5RZ3kyZkxzOTNBRklaeVA2SWE5bTMtaWh0TkRVSHlSM3lFOE55MGJseW15aG1wdHNCMVZVZ2hUc1VUQkpYVUg4OFVjSERFZF9OSzJIZng3WjFyekQzU3A1cGFxM0hDb19mXzdqTWprdW5xdVAwV21jQW5oWTVhZ0VnRlhxZzdab0RIS2hQOThQaXc?oc=5","date":"2026-02-20","type":"earnings","source":"Statista","summary":"Revenue distribution of Menarini 2025, by geographic area - Statista","headline":"Revenue distribution of Menarini 2025, by geographic area","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNR0FpaGxsMDA4TFpLanVYRWFya3Z4RWZVYVJvZTlFa24ydU5mNkY2ckpYOW1iQnNBQ2NaMzRsTGdIdVNtRmdRYUJIWHU3ZzJZUmVSQVBmV0t5cC11c2EzNjM2ak5CTUxyajJhMEJyaDBsQWh0MlVXejFHdGpPSlpuOTJhdHFSekt3SFUtSTBKcHJoY21TeVE?oc=5","date":"2026-02-19","type":"earnings","source":"Statista","summary":"Revenue of Italian pharmaceutical company Menarini from 1964 to 2024 - Statista","headline":"Revenue of Italian pharmaceutical company Menarini from 1964 to 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQaWJFM1VBb24yVW5ZU3U5TndBVUZwT1BqR1cwMEx4cE5jVzIzVGtnTW1mY0kwekJuMnVPOGgwXzIyMUxHQlFueGtaTVotWUZ4eGdzWXVxRTVJaXBZRWtWNEl5aHhyOF9zeXJ4VVpfWGNBcU4zWC1GN1pjM3VqU0RtZkh6cmQwVjFrTlg4S0tJTVpVaVR3SEk0QUl6ZWJFdmJaLXJYM2Z3cFI4QQ?oc=5","date":"2025-12-16","type":"pipeline","source":"BioWorld News","summary":"Menarini sees Asia Pacific as growth engine for its global future - BioWorld News","headline":"Menarini sees Asia Pacific as growth engine for its global future","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-02","type":"regulatory","source":"prnewswire.com","summary":"Menarini Group's Obicetrapib and Obicetrapib/Ezetimibe Marketing Authorisation Applications Accepted for Review by the European Medicines Agency (EMA) for the Treatment of adults with primary hypercho","headline":"Menarini Group's Obicetrapib and Obicetrapib/Ezetimibe Marketing Authorisation Applications Accepted for Review by the E","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNQzZGQy1NRWNPMmk1YUE3SDY4Vm5wLUJ3UlhKQmY2NVhWRk5mbXRyTHBZMUM5YmlZczgxZGtmZVFMcXdrTE5wdGYyZGxFQnpxYkZwM1FKM3VPRHhPbVJqOE10N25RU3ByTUpUYjJvNGU0WVFRS3dISFUxWEtSQU5vQlNiNllBeEtJdzR2a1FWaWRjRWRvX3NxcC03d2dVYUJnVkIxaF8zbzhyTWhVQ1ZqazdXdm43WTlMRjlQNW5B?oc=5","date":"2025-07-23","type":"pipeline","source":"McKinsey & Company","summary":"Bold moves, bolder vision: A CEO’s path for innovative pharma - McKinsey & Company","headline":"Bold moves, bolder vision: A CEO’s path for innovative pharma - McKinsey & Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE1xaFJISGJLQTNyeVVZS1kwWjhEWTdqeXN2di03TktqaTN1VldaamYydDlhUzJINlB3Q3FiNEl2VndRbzRnQjEtNmxVekh5cFVaT2Z0aFBXc1lDbzZ3?oc=5","date":"2025-01-10","type":"deal","source":"EurekAlert!","summary":"Menarini Group and Insilico Medicine enter a second exclusive global license agreement for an AI discovered preclinical asset targeting high unmet needs in oncology - EurekAlert!","headline":"Menarini Group and Insilico Medicine enter a second exclusive global license agreement for an AI discovered preclinical ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQVm96Wm5YSlIxNEZ2WVlZaDNKMk9LRjA0M1RneXR6NEQ2ZVh4bzN1TDZ2T2c3aTJrUktSTzExdE5JbmQ4RWs5empzQ0FEN1ExMnNNY0dZLUlOZVpuRUtRTVpCZTFyenh1XzAxYUUtQkJjX053YkppTjNuMVRMUUxfMWhNaTFVWEZ5NjZnNXdXdXQ0Y3NwVkVmUWN5YmdHZ0F1UnNUaVpvengyTG5tLXZnMXZzdUFXZF9uWVRJ?oc=5","date":"2025-01-10","type":"deal","source":"Contract Pharma","summary":"Menarini Group Licenses Preclinical Oncology Asset from Insilico Medicine - Contract Pharma","headline":"Menarini Group Licenses Preclinical Oncology Asset from Insilico Medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE9EV2k4VVdLQWdBTjM5RnQ0UHpGU21uakFQZmF4cE9ZMjFfNllWd18yMlFReHY1YThNWEFRM0sxUWFRdU1zUHBOQ3RTVXY1S1VVYVp3SXNB?oc=5","date":"2024-10-30","type":"pipeline","source":"Kuehne+Nagel","summary":"Menarini selects Kuehne+Nagel to deliver consumer healthcare across Türkiye - Kuehne+Nagel","headline":"Menarini selects Kuehne+Nagel to deliver consumer healthcare across Türkiye - Kuehne+Nagel","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-11-07","type":"deal","source":"businesswire.com","summary":"Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer ","headline":"Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxNWGZhT215cUoydW14dVZ6QzBrODZCaVhPeWRsQTNwZ0M4MENlMkN0X2phUVJvY0s4QUNOYXgzdXhFWXMyQ1VrZnNJRllVNkdDbXZVZ0ZDOVpDVV9mY2s0R0pIaTg3RW1nZGQ4Nkd5bWJxOFVxN1hRaE13LU5aMHhrWWs4RE5OMkRWNE1zZi1jNmEwZlNGYm9DVjJHNXV1VHlBM0JwNVprUFZBYUlHMEowUE81M0h0UHhUSUQwT1FwU1dGR2ZoR2oxRmxlT21UUlVac2hTMmE1QW5SbmFiM3h4anY0ZC01ZzNHNWwyNkY1enQtSHlraUhGV2M1ME9ZdXNOTXdNYU0xbFR1Znpid2hnLXg0cS1OMXhRcDIzVHlR?oc=5","date":"2021-12-21","type":"deal","source":"Karyopharm","summary":"Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories - Karyopharm","headline":"Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe an","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOWHdqX19vOXNxa3pVODZTajUyUF9oZlh3Tk1YRGJTTGdYb1RIekV6bzBNZVl3TW1pOE4zNUlwbUMzY3VuZUI2X21YLU9adDFlTUJsNUNOZHdKamZxeU1BTFJJT21xVlF6cUc1c1JfY2VwNkdMb2JVRUF0LUVfU1FWaEVIRkJDYV9OWlFR?oc=5","date":"2020-05-05","type":"deal","source":"Pharmaceutical Technology","summary":"Menarini Group to buy Stemline Therapeutics in deal valued at $677m - Pharmaceutical Technology","headline":"Menarini Group to buy Stemline Therapeutics in deal valued at $677m","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}